回复: 迷迷糊糊的疱疹系列研究----先从感叹开始
联合医疗集团：Coridon针对HPV的15亿美元的市场，开发新一代疫苗
Tuesday, February 28, 2012 by Angela Kean 2012年2月28日，由安吉拉·基恩
下一代治疗人类乳头状瘤病毒疫苗被Coridon，联合医疗集团是大股东在公司的发展，有可能超过每年15亿美元的收入。
Allied Healthcare Group's ( ASX: AHZ ) investment company Coridon is developing a next generation therapeutic Human Papillomavirus (HPV) vaccine targeting one of the most common sexually transmitted diseases in the world.联合医疗集团（ ASX：AHZ ）投资公司Coridon正在开发新一代治疗人类乳头状瘤病毒（HPV）疫苗针对在世界上最常见的性病疾病之一。
HPV is associated with several human cancers, most notably cervical cancer.人乳头状瘤病毒与多种人类癌症，最显着的子宫颈癌。
Cervical cancer is the second largest cause of cancer deaths in women worldwide.子宫颈癌是全球妇女癌症死亡的第二大原因。
Globally, this equates to 510,000 cases per year, and about 288,000 deaths, according to the World Health Organization.在全球范围内，这相当于51万例，每年约288,000人死亡，根据世界卫生组织。
In the US alone, about $1.7 billion is spent each year to treat cervical cancer.仅在美国，约1.7亿美元，每年花在治疗宫颈癌。
To give an indication of the revenue potential of a HPV vaccine, the two currently used HPV vaccines generate in excess of $1.5 billion in sales annually.给了HPV疫苗的潜在收入的迹象，目前使用的两种HPV疫苗产生超过美元，年销售额1.5亿元。
Coridon's HPV vaccine has been designed to combat existing infection with the HPV virus, to prevent and treat cervical and other HPV-associated cancers. coridon的人乳头状瘤病毒疫苗已旨在打击现有的HPV病毒感染，预防和治疗子宫颈癌和其他HPV相关癌症。
The development program will be based on preliminary work by Coridon founder Professor Ian Frazer's team and follows on from Frazer's work that resulted in the successful cervical cancer preventative vaccines – Gardasil®, marketed by Merck, and Cervarix, marketed by GlaxoSmithKline.发展计划，将前期工作的基础上，由Coridon创始人伊恩·弗雷泽教授的研究小组，从弗雷泽的工作如下成功宫颈癌预防疫苗 - Gardasil的®，由默克公司销售和Cervarix，由葛兰素史克公司销售。
Coridon will initially collaborate with the University of Queensland's Diamantina Institute to test the vaccine in pre-clinical models that they have established. coridon将最初的昆士兰曼蒂纳研究所与大学合作，在临床前，他们已经建立的模型，以测试疫苗。
Allied Healthcare Group managing director Lee Rodne told Proactive Investors today the vaccine is targeted for the global market as a therapeutic for HPV.联合医疗集团董事总经理李Rodne今天向主动投资者作为人乳头状瘤病毒治疗疫苗是针对全球市场。
"The current vaccine on the market prevents against HPV (and cervical cancer) but doesn't treat it. This vaccine is targeted towards treatment," he said. “目前市场上的疫苗防止对人乳头状瘤病毒（宫颈癌），但不治疗，这种疫苗对治疗有针对性的，”他说。
Coridon's DNA vaccine technologies differ from conventional vaccines in that they offer both preventative and therapeutic value and have the potential to be delivered with a range of adjuvants. coridon的DNA疫苗技术不同于传统的疫苗，他们提供预防和治疗价值，并有可能要与佐剂的范围内交付。
The technology, which is covered by six granted US patents, enhances protein expression in the cell or tissue targeted and results in an improved humoral response.覆盖，这是由6个获得美国专利技术，提高蛋白表达在细胞或有针对性的组织和一个改进的体液免疫反应的结果。
“The work by Professor Frazer's team at Coridon has significant potential globally to treat those patients already infected with the virus, something the current vaccines cannot do,” Rodne said. “弗雷泽教授的研究小组在Coridon的工作具有的巨大潜力，在全球范围内治疗这些患者已经感染病毒，目前的疫苗不能做的事，”Rodne说。
He said the next step in the development of the vaccine is pre-clinical and beginning a phase 1 human study.他说，在疫苗发展的下一步是临床前和开始第一阶段的人体试验。
Allied Healthcare Group is a major investor in Coridon and in October last year increased its investment to help Coridon begin manufacturing and undertake formal pre-clinical safety studies before testing its prototype Herpes Simplex Virus 2 vaccine in a Phase I clinical study.联合医疗集团是一家主要投资者在Coridon和10月，去年增加了其投资，帮助Coridon开始制造和进行正规的临床前安全性研究之前，测试它的原型疱疹单纯病毒疫苗I期临床研究。
